Dave Hart

President

David Hart - President

It is an honor to sit down to craft a letter to our valued customers after a year of change for Bionix Radiation Therapy. The reason for this letter is to briefly update our loyal customers and partners of our current state of Bionix Radiation Therapy, and take a quick look into the future.

In 2016 Bionix RT underwent several changes, including the merge of Bionix RT and Ancer Medical to form the NEW Bionix Radiation Therapy (BRT). The merge is directly aligned to our strategy of collaborating with healthcare professionals, and providing solutions for the most complex cancers while maintaining our strategy to arm those who fight, to defeat cancer. We added the new brachytherapy product line to our portfolio, giving our customers complete solutions for radiation oncology using the most sleek, precise and innovative technology on the market. BRT has heard the request from clinicians to have access to improved disruptive innovation while creating ease of use to accelerate adoption.

The utilization of precision balloon technology continues to be a cutting-edge aspect of our portfolio.  We have aligned our organization to better anticipate the needs of this fight to defeat cancer and to arm those who are fighting cancer with better tools and greater options. This allows clinicians the ability to use the correct tools for the job instead of asking the care givers to adapt their system to the patient. Instead, we offer a complete “tool box” of options and do the best for each individual case presented. The expansion of tools is being driven by collaboration from both clinical and engineering resources.

We have big goals for 2017. BRT is committed to listening to the needs of providers while continuing our collaboration with clinicians to enhance the treatment of radiation therapy and brachytherapy. BRT is striving to being “easy to do business with” and making implementation of disruptive technology as streamlined as possible, keeping increased efficiency in workflow at front of mind.

Arming those to defeat cancer is our primary goal. I know I speak for many when I say we live to hear the “bell” at the end of treatment. That sound is music to ears of those who are front line while fighting cancer.

Respectfully,